Substantial rise in sparteine metabolic ratio during haloperidol treatment.

Authors:

Abstract
A sparteine test was carried out in 14 patients suffering from acute schizophrenic psychoses before and 1‐2 times during oral haloperidol treatment in doses of 10‐40 mg day‐1. In patients classified as extensive metabolisers (sparteine MR less than 20 before treatment), haloperidol treatment resulted in a rise in sparteine MR that correlated with the serum‐haloperidol concentration both within and between patients. At the highest serum haloperidol concentrations (60‐ 80 nM) an increase in sparteine MR by a factor 15‐50 was seen, but no patients were transformed into phenotypically poor metabolisers. The steady state concentration of haloperidol on the initial standard dose of 10 mg day‐1 was the same in one patient classified as a sparteine poor metaboliser (MR = 112) as in eleven patients classified as extensive metabolisers (MR:0.22‐1.47).

This publication has 18 references indexed in Scilit: